rAAV Vector Serotype Matching for Site-Specific Genome Integration

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Recombinant AAV (rAAV) lacks the ability to integrate into a host genome in a site-specific manner and achieving high yield is difficult with typical production procedures.

Innovation Solution

The use of AAV2 or AAV6 inverted terminal repeats (ITRs) and Rep proteins from the same serotype to package rAAV particles, resulting in site-specific integration and increased particle titer and transduction efficiency.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If typical rAAV production procedures are used, then the production process is simple, but the particle titer is low

Engineering Contradiction:

Improveparticle titerVSAvoidproduction yield

Core Design Contradiction:

Quantity of substanceVSProductivity

Solution Approach 1:

The patent changes the serotype matching parameters between ITRs and Rep proteins, specifically using AAV2 ITRs with AAV2 Rep proteins or AAV6 ITRs with AAV6 Rep proteins to achieve site-specific integration and increase particle titer, resolving the contradiction between production simplicity and low yield

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates a composite system by combining specific ITR sequences with corresponding Rep proteins from the same serotype, forming a functional复合 that enables both site-specific integration and high-titer particle production, addressing the low productivity issue

Inventive Principle:

Principle #40Composite materials

2Reliability

If rAAV is used for gene therapy, then the transduction efficiency is limited, but the safety profile is good

Engineering Contradiction:

Improvetransduction efficiencyVSAvoidintegration capability

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts and utilizes the Rep protein's site-specific integration function while maintaining rAAV's safe transduction properties, separating the integration capability from the transduction mechanism to improve reliability without introducing harmful factors

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The Rep protein acts as an intermediary that mediates site-specific integration of the rAAV genome into host cell chromosomes, enabling stable long-term expression while maintaining the safety profile of rAAV transduction

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS20250369014A9Site-specific integrating recombinant AAV vectors for gene therapy and improved production methods

Publication Date: 2025.12.04 UNIV OF FLORIDA RESEARCH FOUNDATION INC

AI summary

Provided herein are methods of site-specific integration of a heterologous sequence into a host genome (e.g., by administering a recombinant adeno-associated virus (rAAV) to a host cell in the presence of a Rep protein), and methods for treating diseases and disorders by delivering an rAAV that comprises a nucleic acid vector comprising a Rep protein. Also provided herein are methods and compositions for producing rAAV particles with improved titer and transduction efficiencies.